Back to Journals » Infection and Drug Resistance » Volume 15

COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine Effectiveness [Corrigendum]

Authors Reynolds MW, Xie Y , Knuth KB , Mack CD, Brinkley E, Toovey S, Dreyer NA 

Received 8 September 2022

Accepted for publication 8 September 2022

Published 20 September 2022 Volume 2022:15 Pages 5543—5544

DOI https://doi.org/10.2147/IDR.S389192



Reynolds MW, Xie Y, Knuth KB, et al. Infect Drug Resist. 2022;1:5167–5182.

Page 5172, Figure 2, the text “7,352 completed vaccine regimen” should read “7,532 completed vaccine regimen” and “1,014 never reported infection” should read “1,414 never reported infection”. The correct Figure 2 is as follows.

Figure 2  Flowchart of study sample and participant counts with COVID-19 infection.

Page 5172, COVID-19 Infected Study Participants section, 2nd line, the text “(31.8% and 20.3%, were college-educated versus 40.5% among fully vaccinated)” should read “(31.8% and 20.3%, were above-college-educated versus 40.5% among fully vaccinated)”.

Page 5172, COVID-19 Symptoms and Impact Among Vaccinated vs Unvaccinated section, 2nd paragraph, line 6, the text “1.6% among the 198 infected after partial vaccination, and 2.0% among the 3018 infected while unvaccinated” should read “2.0% among the 198 infected after partial vaccination, and 1.6% among the 3018 infected while unvaccinated”.

The authors apologize for any confusion this may have caused.


Read the original article


Creative Commons License © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.